BackSutro Biopharma Overview
Sutro Biopharma Inc

Sutro Biopharma Target Price

Analysts' average 12-month price target for Sutro Biopharma is $51.

Get informed when a big investor buys or sells

+ Follow

Share Price

$20.54

Average Target Price

$51.17149.1% upside

6 analysts in the last 4 months

High: $60 | Low: $43

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Stifel NicolausLaura Prendergast$48133.7% upsideOpen
2026-06-11Truist Financial$50143.4% upsideOpen
2026-05-28BarclaysLukas Shumway$56172.6% upsideOpen
2026-05-15Wedbush$60192.1% upsideOpen
2026-05-15H.C. WainwrightAndrew Fein$50143.4% upsideOpen
2026-05-15Leerink Partners$43109.3% upsideOpen
2026-04-30Mizuho Securities$50143.4% upsideOpen
2025-03-14Piper Sandler$202.6% downsideOpen
2024-10-11Bank of America SecuritiesTazeen Ahmad$120484.2% upsideOpen
2024-10-11H.C. WainwrightAndrew Fein$120484.2% upsideOpen
2024-08-16Truist FinancialAsthika Goonewardene$150630.3% upsideOpen
2024-05-14Deutsche BankJames Shin$100386.9% upsideOpen
2024-05-14WedbushDavid Nierengarten$80289.5% upsideOpen
2024-04-03OppenheimerJay Olson$100386.9% upsideOpen
2024-04-03Piper SandlerEdward Tenthoff$110435.5% upsideOpen
2024-04-02Truist FinancialAsthika Goonewardene$180776.3% upsideOpen
2023-01-13Truist Financial$2501117.1% upsideOpen
2023-01-10Piper Sandler$180776.3% upsideOpen
2022-06-28Piper SandlerEdward Tenthoff$160679% upsideOpen

Sutro Biopharma (STRO) FAQ

Sutro Biopharma's target price stands at $51. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $51 for STRO implies 149.1% upside versus today's price ($20.54). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Sutro Biopharma's target price evolved across reporting periods, while the comparison chart places STRO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Sutro Biopharma's reading of $51 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.